RANKL inhibition may prove effective in treatment of human malignancy, suggests study

[News]

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

More... (http://www.news-medical.net/news/20100420/RANKL-inhibition-may-prove-effective-in-treatment-of-human-malignancy-suggests-study.aspx)